Exopharm
Exopharm is a Melbourne-based, ASX-listed clinical-stage biotechnology company founded in 2013, developing exosome-based therapeutics and diagnostics for regenerative medicine applications targeting biotechnology and pharmaceutical companies.
- Company typePrivate
- Founded2013
- HeadquartersMelbourne, Australia
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Exopharm does
Exopharm is a clinical-stage biotechnology company headquartered in Melbourne, Australia, developing exosome-based therapeutics and diagnostics for human regenerative medicine. Founded in 2013 by Dr. Ian Dixon, the company is publicly listed on the Australian Securities Exchange under the ticker EX1 and employs between 11 and 50 people. Exopharm operates in the emerging exosome technologies sector, which is projected to reach $0.3 billion in market size by 2030 at a 28.0% compound annual growth rate.
The company's core technology centers on exosomes — small extracellular vesicles — as a platform for both therapeutic and diagnostic product development. Exopharm targets biotechnology and pharmaceutical companies working on exosome-based products, addressing commercialization challenges in a market where no FDA-approved exosome products currently exist. The company's value proposition is enabling the development of exosome-based therapeutic and diagnostic products aligned with personalized medicine needs.
Exopharm's revenue model and pricing structures are not publicly disclosed in available sources, consistent with a pre-commercial clinical-stage profile. Broader industry strategic partnerships and acquisitions involving exosome-based therapeutics and diagnostics are estimated at approximately $1 billion, signaling significant capital deployment in the sector. At the time of data collection, the company's public website was returning a default cPanel server configuration page, suggesting a possible lapse in digital operations or hosting configuration that potential investors and partners should verify.
Exopharm firmographics
Firmographics- Name
- Exopharm
- Website
- https://exopharm.com
- Company type
- Private
- Founded year
- 2013
- Headcount range
- 11–50 employees
- Short description
- Exopharm is a Melbourne-based, ASX-listed clinical-stage biotechnology company founded in 2013, developing exosome-based therapeutics and diagnostics for regenerative medicine applications targeting biotechnology and pharmaceutical companies.
- Ownership category
- akta.pro rank
Exopharm industry classification
Industry- Product category
- Exosome Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Exosome & Extracellular Vesicle (EV) Therapeutics (HLAMANAE)
- akta.pro secondary industry
- Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL)
Keywords
Where Exopharm is headquartered
LocationHeadquarters
- HQ city
- Melbourne
- HQ country
- Australia
- HQ region
- Oceania
Markets served
Exopharm business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Exopharm product offering
Product offeringCore offering
Exopharm develops exosome-based therapeutic and diagnostic products for human regenerative medicine applications. The company leverages proprietary exosome technologies to create cell-free therapies and diagnostics targeting the biotechnology and pharmaceutical industry. The offering addresses commercialization and regulatory challenges in an emerging market with no FDA-approved exosome products to date.
Differentiator
Problem solved
Functional benefit
Products and services
- Exosome-Based Therapeutics
Companies that use Exopharm
Customer profileSegments1 record
Ideal customer profiles1 record
Exopharm technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Exopharm partnerships and signals
Strategic signalScale indicators3 records
Recent moves4 records
Expansion highlights3 records
Exopharm competitors and assessment
Company assessmentDirect peers
- Capricor Therapeutics: Clinical-stage biotech developing exosome-based therapeutics (notably CAP-1002 and its exosome program, StealthX). Closely comparable to Exopharm in modality, stage, and therapeutic focus on regenerative exosome medicines.
- ExoCoBio: Clinical-stage exosome therapeutics company developing stem cell-derived exosome products for regenerative and aesthetic medicine. Directly comparable to Exopharm in exosome modality and therapeutic focus.
- Regeneus: Australia-based clinical-stage regenerative medicine company developing cell-based and exosome-related therapies. Closely comparable to Exopharm in geography, size, and regenerative medicine focus.
- Evox Therapeutics: UK-based clinical-stage company engineering exosome therapeutics for rare diseases and CNS indications. Directly comparable to Exopharm in modality and stage, with overlapping target indications in regenerative medicine.
- Cynata Therapeutics: ASX-listed (CYP) clinical-stage regenerative medicine company developing stem cell-derived therapeutics. Comparable to Exopharm as a small-cap ASX-listed regenerative medicine peer using biologic-based approaches.
- Codiak BioSciences: Was a clinical-stage developer of engineered exosome therapeutics (engEx platform) for oncology and rare diseases; operates in the same exosome therapeutic modality as Exopharm even though the company has undergone restructuring.
Broad incumbents
- Mesoblast: ASX-listed (MSB) clinical-stage regenerative medicine company with approved and late-stage cell therapy products. Comparable to Exopharm as a fellow ASX-listed regenerative medicine biotech pursuing cell-based and biologic therapies.
Regional players
- ReNeuron: UK-listed clinical-stage regenerative medicine company developing stem cell therapies for stroke and retinal disease. Comparable to Exopharm in modality (regenerative biologics) and clinical-stage profile, but in a different geography.
Others
- Stemcell Technologies: Major supplier of cell culture and regenerative medicine research tools, including exosome-related reagents. Adjacent ecosystem participant to Exopharm, enabling exosome research but not a direct therapeutic competitor.
Emerging players
- ILIAS Biologics: Clinical-stage biotech developing exosome-based therapeutics, including engineered extracellular vesicles for inflammatory and rare diseases. Comparable to Exopharm in modality with a similar therapeutic focus on biologics delivery via exosomes.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Exopharm social profiles
Digital presenceExopharm financial estimates
Financial estimateRevenue estimate
Valuation estimate
Exopharm leadership team
Management profileNumber of profiles
Profiles2 records
Exopharm funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Exopharm M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Exopharm
What does Exopharm do?
Exopharm develops exosome-based therapeutic and diagnostic products for human regenerative medicine applications. The company leverages proprietary exosome technologies to create cell-free therapies and diagnostics targeting the biotechnology and pharmaceutical industry. The offering addresses commercialization and regulatory challenges in an emerging market with no FDA-approved exosome products to date.
When was Exopharm founded?
Exopharm was founded in 2013. It employs 11 to 50 people.
Where is Exopharm based?
Exopharm is headquartered in Melbourne, Australia, in the Oceania region.
Who are Exopharm's main competitors?
Direct peers on record are Capricor Therapeutics, ExoCoBio, Regeneus, Evox Therapeutics, Cynata Therapeutics and Codiak BioSciences. Mesoblast is listed as a broad incumbent. ReNeuron is listed as a regional player. Stemcell Technologies is listed as an others. ILIAS Biologics is listed as an emerging player.
Does Exopharm have an API?
No public API is recorded for Exopharm.
What industry is Exopharm in?
Exopharm's product category is Exosome Therapeutics. Its primary akta.pro industry code is HLAMANAE, Exosome & Extracellular Vesicle (EV) Therapeutics, with a secondary code of HLAAAGAL, Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics). Its NAICS code is 325414 and its SIC code is 2836.